Emcure Pharmaceuticals Ltd.
NSE: EMCURE
Prev Close
1470.1
Open Price
1515
Volume
46,641
Today Low / High
1489.5 / 1532.1
52 WK Low / High
889 / 1585.6
Range
1,438 - 1,590
Currently, the stock is trading on the National Stock Exchange (NSE). The stock price stands at 1514.1, with a change of 44 (2.99299%). The expected target range on the NSE is between 1,438 - 1,590. The stock is trending upwards on the NSE, which could present a good opportunity for potential investors.
Emcure Pharmaceuticals Ltd. Graph
Emcure Pharmaceuticals Ltd. Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Emcure Pharmaceuticals Ltd. T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 1,514.10, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 1,514.10 | 1,529.24 | 1,376.32 - 1,682.17 |
| 1,544.38 | 1,235.51 - 1,853.26 | ||
| 1,559.52 | 1,091.67 - 2,027.38 | ||
| Bearish Scenario | 1,514.10 | 1,498.96 | 1,349.06 - 1,648.85 |
| 1,483.82 | 1,187.05 - 1,780.58 | ||
| 1,468.68 | 1,028.07 - 1,909.28 |
Overview of Emcure Pharmaceuticals Ltd.
ISIN
INE168P01015
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
247,914
Market Cap
286,747,424,004
Last Dividend
3
Official Website
IPO Date
2024-07-10
DCF Diff
N/A
DCF
0
Financial Ratios Every Investor Needs
Stock Dividend of EMCURE
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-08-14 | August 14, 25 | 3 | 3 | 2025-08-14 | 2025-09-27 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| No annual financial income report data available. | |||||||||||
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No annual financial balance sheet data available. | ||||||||||||
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| No annual financial cash flow statement data available. | |||||||||||
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 2,269.82 Cr | 889.53 Cr | 1,380.29 Cr | 0.6081 | 334.48 Cr | 243.46 Cr | 12.85 | 478.60 Cr | 0.1073 |
| 2025-06-30 | 2,100.54 Cr | 802.01 Cr | 1,298.52 Cr | 0.6182 | 304.43 Cr | 206.95 Cr | 10.92 | 416.97 Cr | 0.0985 |
| 2025-03-31 | 2,028.52 Cr | 1,067.77 Cr | 960.75 Cr | 0.4736 | 293.09 Cr | 188.96 Cr | 0.00 | 360.70 Cr | 0.0932 |
| 2024-12-31 | 1,962.63 Cr | 782.73 Cr | 1,179.90 Cr | 0.6012 | 264.94 Cr | 153.72 Cr | 8.12 | 358.50 Cr | 0.0783 |
| 2024-09-30 | 2,001.98 Cr | 788.67 Cr | 1,213.32 Cr | 0.6061 | 283.98 Cr | 194.57 Cr | 10.38 | 416.53 Cr | 0.0972 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 472.25 Cr | 129.29 Cr | 601.54 Cr | 2,299.86 Cr | 2,304.58 Cr | 5,605.54 Cr | 2,439.79 Cr | 9,392.54 Cr | 4,508.51 Cr |
| 2025-03-31 | 121.82 Cr | 76.04 Cr | 197.87 Cr | 2,055.44 Cr | 1,931.81 Cr | 4,555.86 Cr | 2,444.05 Cr | 8,232.72 Cr | 3,591.17 Cr |
| 2024-09-30 | 162.08 Cr | 169.72 Cr | 331.80 Cr | 2,029.49 Cr | 1,751.59 Cr | 4,455.85 Cr | 2,380.66 Cr | 8,124.48 Cr | 3,821.15 Cr |
| 2024-03-31 | 108.96 Cr | 289.22 Cr | 398.17 Cr | 1,938.19 Cr | 1,525.10 Cr | 4,259.92 Cr | 2,411.26 Cr | 7,806.16 Cr | 4,684.40 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| No quarterly financial cash flow statement data available. | |||||||||
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,682.70 | ₹4,037,360,954,019.00 | ₹2,175,122.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,244.50 | ₹1,657,718,547,810.00 | ₹98,152.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹4,042.00 | ₹1,367,996,468,480.00 | ₹159,874.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,224.00 | ₹1,019,063,464,560.00 | ₹528,921.00 |
| Lupin Limited | LUPIN | ₹2,169.00 | ₹990,797,031,000.00 | ₹204,948.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹900.35 | ₹905,962,772,897.00 | ₹271,538.00 |
| Mankind Pharma Limited | MANKIND | ₹2,122.90 | ₹876,343,887,349.00 | ₹63,792.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,230.40 | ₹714,618,316,939.00 | ₹978,482.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,667.50 | ₹677,634,637,500.00 | ₹34,484.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,964.00 | ₹554,242,388,876.00 | ₹162,495.00 |
| Laurus Labs Limited | LAURUSLABS | ₹981.65 | ₹529,950,213,720.00 | ₹735,288.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,450.20 | ₹367,921,856,944.00 | ₹22,979.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,793.20 | ₹348,970,184,957.00 | ₹14,592.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,896.40 | ₹304,248,934,000.00 | ₹55,916.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,514.10 | ₹287,031,782,814.00 | ₹46,641.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,359.00 | ₹220,826,857,671.00 | ₹314,141.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,670.50 | ₹216,762,500,000.00 | ₹3,564.00 |
| Eris Lifesciences Limited | ERIS | ₹1,423.60 | ₹193,918,366,028.00 | ₹40,260.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,510.00 | ₹173,331,800,390.00 | ₹33,838.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹989.10 | ₹156,643,517,747.00 | ₹39,283.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹789.85 | ₹155,255,383,491.00 | ₹36,998.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹848.30 | ₹151,938,902,721.00 | ₹280,562.00 |
| Cohance Lifesciences Limited | COHANCE | ₹384.50 | ₹147,097,065,330.00 | ₹110,639.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,841.60 | ₹139,983,139,354.00 | ₹33,193.00 |
| Granules India Limited | GRANULES | ₹567.25 | ₹137,653,829,151.00 | ₹190,121.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹946.40 | ₹116,157,350,400.00 | ₹28,498.00 |
| Viyash Scientific Limited | VIYASH | ₹214.98 | ₹93,775,471,074.00 | ₹766,380.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,247.00 | ₹87,096,957,354.00 | ₹9,080.00 |
| Strides Pharma Science Limited | STAR | ₹852.40 | ₹78,568,023,257.00 | ₹112,827.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹785.50 | ₹71,203,449,437.00 | ₹51,323.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹445.80 | ₹68,252,897,456.00 | ₹28,558.00 |
| FDC Limited | FDC | ₹380.50 | ₹61,949,236,962.00 | ₹42,113.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹297.35 | ₹58,156,252,988.00 | ₹194,189.00 |
| Sequent Scientific Limited | SEQUENT | ₹202.40 | ₹50,564,340,966.00 | ₹13,647.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹139.17 | ₹45,163,669,402.00 | ₹1,180,523.00 |
| Innova Captab Limited | INNOVACAP | ₹728.45 | ₹41,685,499,530.00 | ₹27,907.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹397.55 | ₹36,284,388,500.00 | ₹90,829.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹325.30 | ₹35,446,400,705.00 | ₹46,236.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹674.65 | ₹34,217,644,188.00 | ₹24,730.00 |
| Suven Life Sciences Limited | SUVEN | ₹142.85 | ₹32,494,660,900.00 | ₹92,987.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹1,963.50 | ₹32,474,355,953.00 | ₹9,519.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹302.00 | ₹30,285,316,812.00 | ₹34,224.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹396.05 | ₹27,884,197,288.00 | ₹19,688.00 |
Key Executives
Gender: Not Specified
Year Born: 1952
Gender: male
Year Born: 1988
Gender: male
Year Born:
Gender: male
Year Born:
Gender: male
Year Born: 1982
Gender: male
Year Born: 1967
Gender: male
Year Born: 1951
Gender: male
Year Born: 1963
Gender: male
Year Born:
Gender: male
Year Born: 1976
Gender: female
Year Born: 1977
FAQs about Emcure Pharmaceuticals Ltd.
The CEO is Satish Ramanlal Mehta.
The current price is ₹1,512.60.
The range is ₹889-1585.6.
The market capitalization is ₹28,674.74 crores.
The dividend yield is 0.20%.
The P/E ratio is 36.14.
The company operates in the Healthcare sector.
Overview of Emcure Pharmaceuticals Ltd. (ISIN: INE168P01015) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹28,674.74 crores and an average daily volume of 247,914 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹3.